Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia - PubMed (original) (raw)

. 1993 Aug 20;261(5124):1041-4.

doi: 10.1126/science.8351518.

Affiliations

• PMID: 8351518
• DOI: 10.1126/science.8351518

Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia

P Liu et al. Science. 1993.

Abstract

The pericentric inversion of chromosome 16 [inv(16)(p13q22)] is a characteristic karyotypic abnormality associated with acute myeloid leukemia, most commonly of the M4Eo subtype. The 16p and 16q breakpoints were pinpointed by yeast artificial chromosome and cosmid cloning, and the two genes involved in this inversion were identified. On 16q the inversion occurred near the end of the coding region for CBF beta, also known as PEBP2 beta, a subunit of a heterodimeric transcription factor regulating genes expressed in T cells; on 16p a smooth muscle myosin heavy chain (SMMHC) gene (MYH11) was interrupted. In six of six inv(16) patient samples tested, an in-frame fusion messenger RNA was demonstrated that connected the first 165 amino acids of CBF beta with the tail region of SMMHC. The repeated coiled coil of SMMHC may result in dimerization of the CBF beta fusion protein, which in turn would lead to alterations in transcriptional regulation and contribute to leukemic transformation.

PubMed Disclaimer

Similar articles

• Detection of the chromosome 16 CBF beta-MYH11 fusion transcript in myelomonocytic leukemias.
  Poirel H, Radford-Weiss I, Rack K, Troussard X, Veil A, Valensi F, Picard F, Guesnu M, Leboeuf D, Melle J, et al. Poirel H, et al. Blood. 1995 Mar 1;85(5):1313-22. Blood. 1995. PMID: 7858261
• Overexpression of core-binding factor alpha (CBF alpha) reverses cellular transformation by the CBF beta-smooth muscle myosin heavy chain chimeric oncoprotein.
  Hajra A, Liu PP, Speck NA, Collins FS. Hajra A, et al. Mol Cell Biol. 1995 Sep;15(9):4980-9. doi: 10.1128/MCB.15.9.4980. Mol Cell Biol. 1995. PMID: 7651416 Free PMC article. Retracted.
• Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia.
  Shurtleff SA, Meyers S, Hiebert SW, Raimondi SC, Head DR, Willman CL, Wolman S, Slovak ML, Carroll AJ, Behm F, et al. Shurtleff SA, et al. Blood. 1995 Jun 15;85(12):3695-703. Blood. 1995. PMID: 7780153
• Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia.
  Liu PP, Hajra A, Wijmenga C, Collins FS. Liu PP, et al. Blood. 1995 May 1;85(9):2289-302. Blood. 1995. PMID: 7727763 Review. No abstract available.
• The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
  Lo Coco F, Pisegna S, Diverio D. Lo Coco F, et al. Haematologica. 1997 May-Jun;82(3):364-70. Haematologica. 1997. PMID: 9234595 Review.

Cited by

• Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
  Gabellier L, Peterlin P, Thepot S, Hicheri Y, Paul F, Gallego-Hernanz MP, Bertoli S, Turlure P, Pigneux A, Guieze R, Ochmann M, Malfuson JV, Cluzeau T, Thomas X, Tavernier E, Jourdan E, Bonnet S, Tudesq JJ, Raffoux E. Gabellier L, et al. Ann Hematol. 2024 Mar;103(3):759-769. doi: 10.1007/s00277-024-05623-0. Epub 2024 Jan 26. Ann Hematol. 2024. PMID: 38273140 Free PMC article.
• Case Report: Identification of a novel LYN::LINC01900 transcript with promyelocytic phenotype and TP53 mutation in acute myeloid leukemia.
  Hu C, Dai Q, Zhang R, Yang H, Wang M, Gu K, Yang J, Meng W, Chen P, Xu M. Hu C, et al. Front Oncol. 2023 Dec 1;13:1322403. doi: 10.3389/fonc.2023.1322403. eCollection 2023. Front Oncol. 2023. PMID: 38107067 Free PMC article.
• Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia-initiating CBFB::MYH11 oncofusion protein.
  Day RB, Hickman JA, Xu Z, Katerndahl CD, Ferraro F, Ramakrishnan SM, Erdmann-Gilmore P, Sprung RW, Mi Y, Townsend RR, Miller CA, Ley TJ. Day RB, et al. J Clin Invest. 2023 Dec 7;134(4):e176311. doi: 10.1172/JCI176311. J Clin Invest. 2023. PMID: 38061017 Free PMC article.
• What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?
  DeWolf S, Tallman MS, Rowe JM, Salman MY. DeWolf S, et al. J Clin Oncol. 2023 Oct 10;41(29):4693-4703. doi: 10.1200/JCO.22.02868. Epub 2023 Aug 23. J Clin Oncol. 2023. PMID: 37611216 Free PMC article. Review.
• Targeted in silico characterization of fusion transcripts in tumor and normal tissues via FusionInspector.
  Haas BJ, Dobin A, Ghandi M, Van Arsdale A, Tickle T, Robinson JT, Gillani R, Kasif S, Regev A. Haas BJ, et al. Cell Rep Methods. 2023 May 8;3(5):100467. doi: 10.1016/j.crmeth.2023.100467. eCollection 2023 May 22. Cell Rep Methods. 2023. PMID: 37323575 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations

• Molecular Biology Databases

  • BioCyc
  • Gene Ontology
  • GlyGen glycoinformatics resource
  • Mouse Genome Informatics (MGI)